Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Stomach Neoplasms × andecaliximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1 Pancreatic Neoplasms 1 Gastric Adenocarcinoma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

Capecitabine 67 Oxaliplatin 63 pembrolizumab 61 Cisplatin 49 Fluorouracil 46 Paclitaxel 35 Nivolumab 33 Trastuzumab 29 Leucovorin 26 Docetaxel 22 Irinotecan 19 Ramucirumab 17 Bevacizumab 14 S 1 (combination) 13 Carboplatin 13 Gemcitabine 12 atezolizumab 11 apatinib 11 tislelizumab 10 fludarabine 9 Drug Therapy 9 Cyclophosphamide 9 trastuzumab deruxtecan 7 durvalumab 7 Ipilimumab 7 Injections 7 130-nm albumin-bound paclitaxel 7 titanium silicide 6 bemarituzumab 6 Folfox protocol 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02545504 2020-05-26

GAMMA-1

Gilead Sciences

Phase 3 Completed

432 enrolled 19 charts

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡